Cyclophosphamide-induced cardiomyopathy in a patient with seminoma and a history of mediastinal irradiation.
A 17-year-old man with mediastinal seminoma was treated with chemotherapy and mediastinal irradiation therapy. Then he received high-dose chemotherapy containing cyclophosphamide (CY) followed by autologous peripheral blood stem cell transplantation. He suffered from CY-induced cardiomyopathy beginning six days after the administration of high-dose CY. The predictable factors associated with the onset of CY-induced cardiomyopathy are not precisely known. It is suggested that the history of mediastinal irradiation was responsible for the onset of cardiomyopathy.
Kamezaki
Kenjirou
K
Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki.
Fukuda
Takahiro
T
Makino
Shigeyoshi
S
Harada
Mine
M
D000293:Adolescent; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects*; D001706:Biopsy; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000175:diagnosis; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D004452:Echocardiography; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008479:Mediastinal Neoplasms / Q000175:diagnosis / Q000532:radiotherapy* / Q000556:secondary; D036102:Peripheral Blood Stem Cell Transplantation; D018239:Seminoma / Q000175:diagnosis / Q000556:secondary / Q000628:therapy*; D013736:Testicular Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D014057:Tomography, X-Ray Computed; D014182:Transplantation, Autologous; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide